Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.
Tiacci, E., Mancini, A., Marchetti, M., D'Elia, G.M., Candoni, A., Morotti, A., et al. (2023). SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 201(3), 411-416 [10.1111/bjh.18606].
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia
Gozzetti A.;
2023-01-01
Abstract
Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Br J Haematol - 2022 - Tiacci - SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia.pdf
non disponibili
Descrizione: Free full-text sul sito dell'editore e su PMC per la durata della pandemia COVID-19
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
481.75 kB
Formato
Adobe PDF
|
481.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1224844